晟德 轉投資:轉投資事業助攻晟德首季每股獲利1.67元
轉投資事業助攻晟德首季每股獲利1.67元
Provide From Google
![個股轉投資概況](https://i0.wp.com/api.multiavatar.com/%E5%80%8B%E8%82%A1%E8%BD%89%E6%8A%95%E8%B3%87%E6%A6%82%E6%B3%81-4123.png?apikey=viVnb6N20jclO8)
個股轉投資概況
https://fubon-ebrokerdj.fbs.co
Provide From Google
![晟德(4123) 轉投資| 個股](https://i0.wp.com/api.multiavatar.com/%E6%99%9F%E5%BE%B7%284123%29+%E8%BD%89%E6%8A%95%E8%B3%87%7C+%E5%80%8B%E8%82%A1-+%E8%82%A1%E5%B8%82+-+%E7%90%86%E8%B2%A1%E5%AF%B6.png?apikey=viVnb6N20jclO8)
晟德(4123) 轉投資| 個股
https://www.cmoney.tw
Provide From Google
![晟德轉投資攻標靶藥物](https://i0.wp.com/api.multiavatar.com/%E6%99%9F%E5%BE%B7%E8%BD%89%E6%8A%95%E8%B3%87%E6%94%BB%E6%A8%99%E9%9D%B6%E8%97%A5%E7%89%A9%7C+%E6%AB%83%E8%B2%B7%E5%8B%95%E6%85%8B+-+%E7%B6%93%E6%BF%9F%E6%97%A5%E5%A0%B1.png?apikey=viVnb6N20jclO8)
晟德轉投資攻標靶藥物
https://money.udn.com
晟德(4123)(4123)集團持股四成的建誼生技宣布,將投資6億元打造抗體偶聯藥物(ADC)生產線,目標明年第4季完工投產後,打造建誼為一抗體偶聯 ...
Provide From Google
![轉投資事業挹注,晟德首季每股賺1.67元](https://i0.wp.com/api.multiavatar.com/%E8%BD%89%E6%8A%95%E8%B3%87%E4%BA%8B%E6%A5%AD%E6%8C%B9%E6%B3%A8%EF%BC%8C%E6%99%9F%E5%BE%B7%E9%A6%96%E5%AD%A3%E6%AF%8F%E8%82%A1%E8%B3%BA1.67%E5%85%83+-+MoneyDJ.png?apikey=viVnb6N20jclO8)
轉投資事業挹注,晟德首季每股賺1.67元
https://www.moneydj.com
晟德(4123)公布今(2023)年第一季財報,季營收3.35億元,年增120.39%;毛利率41.96%,年減7.43個百分點;稅後淨利9.92億元,年減27.02%,每股盈餘1.67元。
Provide From Google
![轉投資成長見效,晟德首季EPS 1.67元:2025年將創7](https://i0.wp.com/api.multiavatar.com/%E8%BD%89%E6%8A%95%E8%B3%87%E6%88%90%E9%95%B7%E8%A6%8B%E6%95%88%EF%BC%8C%E6%99%9F%E5%BE%B7%E9%A6%96%E5%AD%A3EPS+1.67%E5%85%83%EF%BC%9A2025%E5%B9%B4%E5%B0%87%E5%89%B57-8%E5%AE%B6%E5%B8%82%E5%80%BC+....png?apikey=viVnb6N20jclO8)
轉投資成長見效,晟德首季EPS 1.67元:2025年將創7
https://www.businesstoday.com.
晟德(4123)週五(5/12)公布2023年Q1財報數字,第一季EPS1.67。其中,營收3.35億元,成長120%; 營業毛利1.4億元,成長87%;稅後淨利近10億。